Acrivon Therapeutics Inc.... (ACRV)
undefined
undefined%
At close: undefined
7.06
-0.28%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.

The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer.

The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase.

The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Acrivon Therapeutics Inc. Common Stock
Acrivon Therapeutics Inc. Common Stock logo
Country United States
IPO Date Nov 15, 2022
Industry Biotechnology
Sector Healthcare
Employees 58
CEO Dr. Peter Blume-Jensen M.D., Ph.D.

Contact Details

Address:
480 Arsenal Way
Watertown, Massachusetts
United States
Website https://www.acrivon.com

Stock Details

Ticker Symbol ACRV
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001781174
CUSIP Number 004890109
ISIN Number US0048901096
Employer ID 82-5125532
SIC Code 2834

Key Executives

Name Position
Dr. Peter Blume-Jensen M.D., Ph.D. Co-Founder, Chairman of the Board, Chief Executive Officer, President & Acting Chief Scientific Officer
Dr. Eric J. Devroe Ph.D. Chief Operating Officer
Mary-Alice Miller J.D. Chief Legal Officer
Rasmus Holm-Jorgensen Chief Financial Officer
Bruce Close Vice President of Quality & Compliance
Dr. Adam D. Levy M.B.A., Ph.D. Senior Vice President and Head of Investor Relations & Corporate Affairs
Dr. Erick Gamelin M.D., Ph.D. Chief Development Officer
Katharine Peterson CPA Vice President of Finance & Accounting
Kristina Masson M.B.A., Ph.D. Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer, Secretary & Director
Parvin Miah Vice President & Head of Human Resources

Latest SEC Filings

Date Type Title
Nov 27, 2024 4 Filing
Nov 27, 2024 4 Filing
Nov 27, 2024 4 Filing
Nov 27, 2024 4 Filing
Nov 27, 2024 4 Filing
Nov 25, 2024 4 Filing
Nov 18, 2024 4 Filing
Nov 18, 2024 4 Filing
Nov 18, 2024 4 Filing
Nov 18, 2024 4 Filing